Adulteration of animal-derived whey protein in infant formula: High-throughput screening of characteristic peptides.

Independent laboratory validation of a Salmonella loop-mediated isothermal amplification assay in 27 human and animal food matrices of 9 ISO food categories.

Antioxidant properties of camel and bovine colostrum upon simulated infant gastrointestinal digestion: Peptide identification, molecular simulation and binding mechanism.

New era to prepare human milk fat substitutes: 1,3-Dioleoyl-2-palmitoyl-glycerol.

Milk and plant lipids influence the in vitro digestion of milk proteins.

Nutritional quality of fatty acids from donated human milk, infant formulas and human milk fortifier

Characterization of different types of micellar casein isolates and comparison of their enzymatic coagulation behavior by chymosin and pepsin.

Microbiological and chemical risks in foods: Public perception versus risk ranking.

Regarding "US infant formulas contain primarily added sugars: An analysis of infant formulas on the US market"

Accuracy assessment of a micro-Raman spectroscopy method for small microplastic particles in infant milk formula

The reactive oxygen species-induced small RNA CsrO promotes the survival of Cronobacter sakazakii in macrophages and systemic infection within the host.

Advances in isolation, composition, properties and applications of milk fat globule membrane proteins: A review.

Opposing regulation of Gig2 by RecA and GlrK controls redox-linked desiccation tolerance in Cronobacter sakazakii.

The influence of dietary structures composed of different fat globule interfaces on lipid metabolism in mice with a high-fat diet.

A multifunctional terbium-based metal-organic framework for ultrasensitive detection of ethyl maltol, gallic acid, and rotenone in complex food matrices.

Insights into the mechanism of phosphatidylcholine-casein interactions in simulated infant formula emulsion: structure, physicochemical properties and microcapsule formation.

Formation of non-enzymatic protein modifications (nePTMs) on caseins and whey proteins during dry heating and the impact on their in vitro infant digestion profile.

Background/objectivesOptimal nutrition in very low birth weight (VLBW) infants is associated with improved clinical outcomes. When parenteral nutrition (PN) with a marketing authorisation is not appropriate, hospital pharmacies can prepare more suitable PN preparation. This corresponds to standard preparations (i.e., available at any time with a fixed composition) or individualised ones (i.e., available after a period of prescription, preparation, and pharmaceutical control). In France, 12 standard formulas to be compounded were proposed by a national consortium in 2018. The objective of the present study was to evaluate whether individualised PN preparations ordered in our hospital are substitutable by one of the 12 standard formulas.MethodsAll PN prescriptions for VLBW infants made in 2021 in our hospital were retrospectively extracted. For each prescription, the theoretical intakes that an infant would have received if a standard preparation had been administered were calculated. Standard and individualised preparations were compared using the Mann-Whitney U test for each component. Secondly, the relative difference between the expected intakes and effectively intakes was calculated for each component.Results/DiscussionOver the study period, 1708 prescriptions were identified (corresponding to 1708 PN individualised preparations). Most infants were extremely low birth weight infants. Based on the methods of comparison, none of the 12 standard formulas fitted with targeted intakes achieved with individualised PN preparations ordered, whereas prescriptions did fit with international guidelines.ConclusionThe study highlights how it is difficult to establish nationally standard PN formulas for VLBW infants; the development of local standard formulas seems therefore relevant.

This study aims to analyze the influence of ethics-based integrated marketing communication on customer value creation and its impact on customer loyalty in the infant formula industry in Indonesia. This industry operates under strict ethical codes set by the World Health Organization (WHO) and reinforced by Indonesian Ministry of Health Decrees No. 237/IV/Menkes/1997 and No. 450/IV/Menkes/2004, prioritizing breastfeeding. However, weak enforcement of ethical codes and the reciprocal relationship between healthcare professionals and companies create potential ethical challenges. The research was conducted in three major cities—Jakarta, Surabaya, and Makassar—using healthcare professionals such as doctors, pediatricians, midwives, and nurses as units of analysis. The study employed interviews and surveys with random and stratified random sampling methods. Primary data were analyzed using Structural Equation Modeling (SEM) via Lisrel 8.70. Results show that ethics-based integrated marketing communication has a positive and significant effect on customer value (coefficient 0.912; t-value 10.29 ? 1.96) but does not directly affect customer loyalty (coefficient 0.009; t-value 0.041 ? 1.96). Indirectly, it significantly influences loyalty through customer value (coefficient 0.849). Customer value has a positive and significant direct effect on loyalty (coefficient 0.931; t-value 4.075 ? 1.96), indicating that customer value acts as a key mediator in enhancing healthcare professionals’ loyalty toward infant formula products.

Treatment of growth faltering in early infancy may improve short and long term child health outcomes. The overall aim of this trial is to determine, in infants who meet study criteria for growth faltering, the effect of intensive breastfeeding counselling and support (IBFCS) plus nutritional milk supplementation (NMS) compared with IBFCS alone, on mortality, morbidity and growth at 6 completed months in low resource settings in South Asia and Sub-Saharan Africa. The primary outcome of the trial is wasting free survival (alive without wasting (weight for length standard deviation score < - 2 standard deviations (SD))) at 6 completed months of age. This is a multi-centre, parallel-group, individually-randomized, non-blinded, controlled trial implemented in seven countries: three in Asia (Bangladesh, India and Pakistan) and four in Africa (Ethiopia, Nigeria, Tanzania and Uganda). Eleven thousand (11,000) infants with a gestational age of at least 28 weeks are enrolled and individually randomised between 7 and 14 days of age. The mother of each infant receives breastfeeding support from trained peer counsellors. Research workers follow up each infant 1-2 weekly at the infant's home to collect growth and outcome data. If infants meet study criteria for growth problems (slow weight gain, growth concern or growth faltering) they are reviewed by study clinicians, their medical problems are treated, and their mothers receive IBFCS. Infants with growth faltering in the intervention arm also receive nutritional milk supplementation (NMS) (prescribed quantities of term infant formula that meets Codex Alimentarius standards calculated to fulfill the needs for catch up growth). The comparison group receives IBFCS alone. Weekly growth monitoring continues and final outcome data (mortality, wasting) are measured in all infants at 6 completed months. This large randomised trial will provide evidence about the role of NMS, if any, in infants with growth faltering who do not respond to IBFCS and treatment of medical problems in low resource settings. Australian and New Zealand Clinical Trial Registry (ANZCTR) CTRN12624000704594. Registered on June 4 2024.